8-K ·Filed May 4, 2026
8-K context-dependent: Items 8.01
Actionable Insight • Neutral
Monitor upcoming quarterly results for any acceleration in revenue growth or commercial execution improvements. The appointment itself is not a stock-moving event.
Final — all horizons settled through T+60d
SEER ▲ +10.75% at T+60d
NEUTRAL call +10.75% · α vs SPY +8.01% · entry $1.86 → $2.06
T+1d
+1.61%
call +1.61% · α +0.23%
$1.89
settled 6mo ago
T+5d
-2.15%
call -2.15% · α -4.13%
$1.82
settled 6mo ago
T+20d
+0.54%
call +0.54% · α -4.42%
$1.87
settled 5mo ago
T+60d
+10.75%
call +10.75% · α +8.01%
$2.06
settled 3mo ago
Price Chart
Loading chart...
Executive Summary
Seer, Inc. appointed Anthony Bazarko as Chief Commercial Officer, a seasoned life sciences executive. The move is a routine executive hire with no immediate financial impact, but may signal focus on commercial execution.
Key Facts
- Anthony Bazarko appointed Chief Commercial Officer on May 4, 2026
- Bazarko brings over 20 years of commercial leadership from Biologos, Specific Diagnostics, Danaher, and Roche
- No financial terms or material agreements disclosed
Financial Impact
No financial impact disclosed in filing
Market Snapshot
Exchange
Nasdaq
Sector
Laboratory Analytical Instruments
Analyst Consensus
86% bullish (7 analysts)
Investment Themes
Industrials & Manufacturing
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-204084 |
| Document: ck0001726445-ex99_1.htm | 0001193125-26-204084 |
| Document: 0001193125-26-204084-index-headers.html | 0001193125-26-204084 |
| Document: 0001193125-26-204084-index.html | 0001193125-26-204084 |
| Document: 0001193125-26-204084.txt | 0001193125-26-204084 |
38 reports for SEER
63% Hit rate @ T+20 Went positive at some point 16 of 16 best @ T+5▲ +31.93%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 6d ago | Press Release | $1.97 | awaiting T+20 | — | $1.93 (−2.03%) |
Oct 15, 2026 13d ago | ITC Section 337 | $2.03 | awaiting T+20 | — | $1.93 (−4.93%) |
Oct 8, 2026 19d ago | 3 | $2.19 | awaiting T+20 | — | $1.93 (−11.87%) |
Sep 21, 2026 5w ago | Press Release | $1.86 $2.02 | ▲ +8.60% | ▲ +9.51% | $1.93 (+3.76%) |
Jul 31, 2026 12w ago | 8-K | $2.22 $1.98 | ▼ −10.81% | ▼ −13.80% | $1.93 (−13.06%) |
Jul 28, 2026 13w ago | Press Release | $2.08 $2.02 | ▲ +2.88% | ▲ +7.90% | $1.93 (+7.21%) |
Jul 28, 2026 13w ago | DFAN14A | $2.14 $2.04 | ▼ −4.67% | ▼ −8.05% | $1.93 (−9.81%) |
Jul 20, 2026 14w ago | DEFA14A | $2.04 $2.03 | ▼ −0.49% | ▼ −4.61% | $1.93 (−5.39%) |
Jul 20, 2026 14w ago | Press Release | $2.04 $2.03 | ▼ −0.49% | ▼ −4.61% | $1.93 (−5.39%) |
Jul 8, 2026 15w ago | DEFA14A | $2.18 $2.19 | ▲ +0.46% | ▼ −2.81% | $1.93 (−11.47%) |
Showing 10 of 38
US Market Status
Market Closed — Opens Thu (13h 14m)
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers